RT Journal Article
SR Electronic
T1 COVID-19 in Japan: What could happen in the future?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.21.20026070
DO 10.1101/2020.02.21.20026070
A1 Nian Shao
A1 Hanshuang Pan
A1 Xingjie Li
A1 Weijia Li
A1 Shufen Wang
A1 Yan Xuan
A1 Yue Yan
A1 Keji Liu
A1 Yu Chen
A1 Boxi Xu
A1 Xinyue Luo
A1 Christopher Y. Shen
A1 Min Zhong
A1 Xiang Xu
A1 Xu Chen
A1 Yu Jiang
A1 Shuai Lu
A1 Guanghong Ding
A1 Jin Cheng
A1 Wenbin Chen
YR 2020
UL http://medrxiv.org/content/early/2020/02/23/2020.02.21.20026070.abstract
AB We adopt a novel statistical time delay dynamic model proposed in our recent work to estimate the evolution of COVID-19. Based on the cumulative number of confirmed cases and cured cases published daily by government, we effectively simulate and predict the outbreak trend of COVID-19 in different regions in China. Meanwhile, the model reveals the growth rate of the epidemic, through which the basic reproductive number is thus estimated to be 3.25 to 3.4. Then, we apply the model to track the spread of COVID-19 in Japan. We find that the trend of the epidemic in Japan is strikingly similar to that in Wuhan, China at the early stage. Therefore there are reasons to draw a serious concern that there could be a rapid outbreak in Japan if no effective control measures are carried out immediately. Finally, we make a prediction of the future trend of COVID-19 in Japan, and suggest an enhancement of control measures as soon as possible, so as to avoid a severe outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWenbin Chen was supported in part by the National Science Foundation of China (11671098, 91630309) and 111 project(B08018), Jin Cheng was supported in part by the National Science Foundation of China (11971121).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from Wind database or any one can find them in the website of Chinese Center for Disease Control and Prevention(CCDC). Only the cumulative numbers in hospitalization are needed.